Tag: alzheimer’s disease diagnostic market trends

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Alzheimer’s Disease Diagnostic Market CAGR Analysis And Future Market Development

The global market for Alzheimer’s disease diagnostics has experienced significant expansion, projected to increase from \$7.26 billion in 2025 to \$8.03 billion in 2026, reflecting a compound annual growth rate of 10.6%. This upward trajectory in the historical period is largely due to the escalating incidence of Alzheimer’s disease, heightened public consciousness regarding neurodegenerative conditions, the expanding use of MRI and PET imaging techniques, the proliferation of diagnostic facilities and healthcare institutions, and increased funding dedicated to research in cognitive assessment.

The market for Alzheimer’s disease diagnostics is poised for significant expansion, projected to reach $11.89 billion by the year 2030, reflecting a compound annual growth rate of 10.3%. This anticipated surge is fueled by advancements in novel biomarkers and imaging tracers, the incorporation of artificial intelligence for earlier identification, increased governmental and private investment in Alzheimer’s research, broader adoption of personalized medicine strategies, and an uptick in multi-center clinical trials. Key developments anticipated during this forecast period encompass a greater reliance on diagnostics that utilize biomarkers, enhanced application of neuroimaging techniques for early detection, an escalation in cognitive assessment testing, expanded genetic testing to evaluate Alzheimer’s risk, and the integration of comprehensive, multi-modal diagnostic methodologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

Alzheimer’s Disease Diagnostic Market Development Factors: Which Trends Are Supporting Demand?

Anticipated expansion in the prevalence of chronic illnesses is poised to spur the advancement of the Alzheimer’s disease diagnostic market. Conditions like heart disease, diabetes, and high blood pressure are significantly linked to a heightened susceptibility to Alzheimer’s and other forms of dementia, consequently boosting the need for diagnostic tools that offer early and precise identification. A primary contributor to this surge in chronic ailments is the pervasive adoption of sedentary habits, as substantial public health studies consistently reveal substantially elevated incidences of conditions such as diabetes and cardiovascular issues within populations that are not physically active. Diagnostic tools for Alzheimer’s offer valuable support to healthcare frameworks by permitting early identification, enabling prompt therapeutic actions, and assisting in the management of patients to potentially decelerate the disease’s advancement. To illustrate, in November 2023, data from Heritage Health Services, a US non-profit health research entity, indicated that 6.7 million individuals over 65 in the United States were coping with Alzheimer’s dementia, with the condition becoming more widespread with advancing age, affecting 5.0% of those aged 65–74, 13.1% of those aged 75–84, and 33.3% of those aged 85 and older. This figure is forecasted to approach 13 million by the year 2050, underscoring how the increasing burden of chronic disease is fueling the growth trajectory of the Alzheimer’s disease diagnostic market.

#Alzheimer’s Disease Diagnostic Market Segment Landscape And Growth Potential

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Alzheimer’s Disease Diagnostic Market Transformation Trends: Which Innovations Are Driving Change?

Key players within the Alzheimer’s disease diagnostics sector are directing their efforts toward the development of blood-based biomarker assays, a strategic move anticipated to streamline the diagnostic pathway for Alzheimer’s, thereby lessening the dependence on more intrusive methods and enhancing the availability of prompt therapeutic interventions for individuals affected. Illustrating this trend, Quanterix, a biotechnology firm based in the United States, introduced the LucentAD p-Tau 217 test in October 2023, a blood-based indicator of Alzheimer’s pathology that exhibits considerable clinical sensitivity and specificity. Conventional diagnostic avenues for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) scans or lumbar punctures, are characterized by their expense, invasive nature, and limited accessibility. The LucentAD test further integrates Quanterix’s highly sensitive SimoaÒ technology with well-validated p-Tau 217 antibodies sourced from J&J Innovative Medicine, ensuring superior precision and a more user-friendly procedure.

Alzheimer’s Disease Diagnostic Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Access The Complete Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

#Alzheimer’s Disease Diagnostic Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Alzheimer’s Disease Diagnostic Market CAGR Analysis And Future Market Development

The global market for Alzheimer’s disease diagnostics has experienced significant expansion, projected to increase from \$7.26 billion in 2025 to \$8.03 billion in 2026, reflecting a compound annual growth rate of 10.6%. This upward trajectory in the historical period is largely due to the escalating incidence of Alzheimer’s disease, heightened public consciousness regarding neurodegenerative conditions, the expanding use of MRI and PET imaging techniques, the proliferation of diagnostic facilities and healthcare institutions, and increased funding dedicated to research in cognitive assessment.

The market for Alzheimer’s disease diagnostics is poised for significant expansion, projected to reach $11.89 billion by the year 2030, reflecting a compound annual growth rate of 10.3%. This anticipated surge is fueled by advancements in novel biomarkers and imaging tracers, the incorporation of artificial intelligence for earlier identification, increased governmental and private investment in Alzheimer’s research, broader adoption of personalized medicine strategies, and an uptick in multi-center clinical trials. Key developments anticipated during this forecast period encompass a greater reliance on diagnostics that utilize biomarkers, enhanced application of neuroimaging techniques for early detection, an escalation in cognitive assessment testing, expanded genetic testing to evaluate Alzheimer’s risk, and the integration of comprehensive, multi-modal diagnostic methodologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

Alzheimer’s Disease Diagnostic Market Development Factors: Which Trends Are Supporting Demand?

Anticipated expansion in the prevalence of chronic illnesses is poised to spur the advancement of the Alzheimer’s disease diagnostic market. Conditions like heart disease, diabetes, and high blood pressure are significantly linked to a heightened susceptibility to Alzheimer’s and other forms of dementia, consequently boosting the need for diagnostic tools that offer early and precise identification. A primary contributor to this surge in chronic ailments is the pervasive adoption of sedentary habits, as substantial public health studies consistently reveal substantially elevated incidences of conditions such as diabetes and cardiovascular issues within populations that are not physically active. Diagnostic tools for Alzheimer’s offer valuable support to healthcare frameworks by permitting early identification, enabling prompt therapeutic actions, and assisting in the management of patients to potentially decelerate the disease’s advancement. To illustrate, in November 2023, data from Heritage Health Services, a US non-profit health research entity, indicated that 6.7 million individuals over 65 in the United States were coping with Alzheimer’s dementia, with the condition becoming more widespread with advancing age, affecting 5.0% of those aged 65–74, 13.1% of those aged 75–84, and 33.3% of those aged 85 and older. This figure is forecasted to approach 13 million by the year 2050, underscoring how the increasing burden of chronic disease is fueling the growth trajectory of the Alzheimer’s disease diagnostic market.

#Alzheimer’s Disease Diagnostic Market Segment Landscape And Growth Potential

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Alzheimer’s Disease Diagnostic Market Transformation Trends: Which Innovations Are Driving Change?

Key players within the Alzheimer’s disease diagnostics sector are directing their efforts toward the development of blood-based biomarker assays, a strategic move anticipated to streamline the diagnostic pathway for Alzheimer’s, thereby lessening the dependence on more intrusive methods and enhancing the availability of prompt therapeutic interventions for individuals affected. Illustrating this trend, Quanterix, a biotechnology firm based in the United States, introduced the LucentAD p-Tau 217 test in October 2023, a blood-based indicator of Alzheimer’s pathology that exhibits considerable clinical sensitivity and specificity. Conventional diagnostic avenues for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) scans or lumbar punctures, are characterized by their expense, invasive nature, and limited accessibility. The LucentAD test further integrates Quanterix’s highly sensitive SimoaÒ technology with well-validated p-Tau 217 antibodies sourced from J&J Innovative Medicine, ensuring superior precision and a more user-friendly procedure.

Alzheimer’s Disease Diagnostic Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Access The Complete Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

#Alzheimer’s Disease Diagnostic Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Alzheimer’s Disease Diagnostic Market CAGR Analysis And Future Market Development

The global market for Alzheimer’s disease diagnostics has experienced significant expansion, projected to increase from \$7.26 billion in 2025 to \$8.03 billion in 2026, reflecting a compound annual growth rate of 10.6%. This upward trajectory in the historical period is largely due to the escalating incidence of Alzheimer’s disease, heightened public consciousness regarding neurodegenerative conditions, the expanding use of MRI and PET imaging techniques, the proliferation of diagnostic facilities and healthcare institutions, and increased funding dedicated to research in cognitive assessment.

The market for Alzheimer’s disease diagnostics is poised for significant expansion, projected to reach $11.89 billion by the year 2030, reflecting a compound annual growth rate of 10.3%. This anticipated surge is fueled by advancements in novel biomarkers and imaging tracers, the incorporation of artificial intelligence for earlier identification, increased governmental and private investment in Alzheimer’s research, broader adoption of personalized medicine strategies, and an uptick in multi-center clinical trials. Key developments anticipated during this forecast period encompass a greater reliance on diagnostics that utilize biomarkers, enhanced application of neuroimaging techniques for early detection, an escalation in cognitive assessment testing, expanded genetic testing to evaluate Alzheimer’s risk, and the integration of comprehensive, multi-modal diagnostic methodologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

Alzheimer’s Disease Diagnostic Market Development Factors: Which Trends Are Supporting Demand?

Anticipated expansion in the prevalence of chronic illnesses is poised to spur the advancement of the Alzheimer’s disease diagnostic market. Conditions like heart disease, diabetes, and high blood pressure are significantly linked to a heightened susceptibility to Alzheimer’s and other forms of dementia, consequently boosting the need for diagnostic tools that offer early and precise identification. A primary contributor to this surge in chronic ailments is the pervasive adoption of sedentary habits, as substantial public health studies consistently reveal substantially elevated incidences of conditions such as diabetes and cardiovascular issues within populations that are not physically active. Diagnostic tools for Alzheimer’s offer valuable support to healthcare frameworks by permitting early identification, enabling prompt therapeutic actions, and assisting in the management of patients to potentially decelerate the disease’s advancement. To illustrate, in November 2023, data from Heritage Health Services, a US non-profit health research entity, indicated that 6.7 million individuals over 65 in the United States were coping with Alzheimer’s dementia, with the condition becoming more widespread with advancing age, affecting 5.0% of those aged 65–74, 13.1% of those aged 75–84, and 33.3% of those aged 85 and older. This figure is forecasted to approach 13 million by the year 2050, underscoring how the increasing burden of chronic disease is fueling the growth trajectory of the Alzheimer’s disease diagnostic market.

#Alzheimer’s Disease Diagnostic Market Segment Landscape And Growth Potential

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Alzheimer’s Disease Diagnostic Market Transformation Trends: Which Innovations Are Driving Change?

Key players within the Alzheimer’s disease diagnostics sector are directing their efforts toward the development of blood-based biomarker assays, a strategic move anticipated to streamline the diagnostic pathway for Alzheimer’s, thereby lessening the dependence on more intrusive methods and enhancing the availability of prompt therapeutic interventions for individuals affected. Illustrating this trend, Quanterix, a biotechnology firm based in the United States, introduced the LucentAD p-Tau 217 test in October 2023, a blood-based indicator of Alzheimer’s pathology that exhibits considerable clinical sensitivity and specificity. Conventional diagnostic avenues for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) scans or lumbar punctures, are characterized by their expense, invasive nature, and limited accessibility. The LucentAD test further integrates Quanterix’s highly sensitive SimoaÒ technology with well-validated p-Tau 217 antibodies sourced from J&J Innovative Medicine, ensuring superior precision and a more user-friendly procedure.

Alzheimer’s Disease Diagnostic Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Access The Complete Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

#Alzheimer’s Disease Diagnostic Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Alzheimer’s Disease Diagnostic Market From 2026 To 2030?

The alzheimer’s disease diagnostic market has experienced substantial expansion in recent years. It is anticipated to grow from $7.26 billion in 2025 to $8.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The historical increase in this market can be ascribed to the rising occurrence of alzheimer’s disease, heightened understanding of neurodegenerative conditions, the use of MRI and PET imaging, the proliferation of diagnostic centers and hospitals, and financial contributions to cognitive assessment research.

The alzheimer’s disease diagnostic market size is poised for significant expansion over the next few years. It is expected to reach $11.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.3%. This anticipated growth is fueled by the development of innovative biomarkers and imaging tracers, the incorporation of AI for earlier detection, increasing government and private funding directed towards Alzheimer’s research, the spread of personalized medicine initiatives, and a rise in multi-center clinical trials. Prominent trends expected during this forecast period include a greater embrace of biomarker-based diagnostics, an increasing application of neuroimaging techniques for early identification, an uptick in cognitive assessment testing, the broadened availability of genetic testing for Alzheimer’s risk evaluation, and the integration of multi-modal diagnostic strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Leading Drivers Are Supporting The Alzheimer’s Disease Diagnostic Market Expansion?

The anticipated expansion of the Alzheimer’s disease diagnostic market is attributed to the rising incidence of chronic diseases. Conditions like cardiovascular disease, diabetes, and hypertension are deeply linked to a heightened risk of Alzheimer’s and other forms of dementia, thereby boosting the need for timely and precise diagnostic tools. A primary contributor to this surge in chronic diseases is the global increase in sedentary habits, with extensive research consistently demonstrating considerably higher rates of conditions like diabetes and cardiovascular disease among those with inactive lifestyles. Alzheimer’s diagnostics aid healthcare systems by facilitating early detection, allowing for prompt interventions, and assisting in patient management to retard the advancement of the disease. For example, data from November 2023, provided by Heritage Health Services, a US-based nonprofit healthcare research organization, indicated that 6.7 million Americans aged 65 or above were affected by Alzheimer’s dementia. The prevalence escalated with age: 5.0% for 65–74 years, 13.1% for 75–84 years, and 33.3% for 85+ years. Projections show this figure reaching almost 13 million by 2050. Consequently, the escalating prevalence of chronic disease is fueling the expansion of the Alzheimer’s disease diagnostic market.

How Is The Alzheimer’s Disease Diagnostic Market Categorized Across Its Segment Groups?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

What Emerging Trends Are Seen In The Alzheimer’s Disease Diagnostic Market?

Leading companies in the Alzheimer’s disease diagnostic market are concentrating on enhancing blood-based biomarker tests, a development expected to streamline the diagnostic process for Alzheimer’s disease. This approach aims to lessen dependence on more invasive procedures and improve patients’ access to timely treatment. For example, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, which serves as a biomarker for Alzheimer’s pathology, demonstrating clinical sensitivity and specificity in blood. Traditional methods for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are often expensive, invasive, and not broadly accessible. Additionally, the LucentAD p-Tau 217 test integrates Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, ensuring remarkable accuracy and a simpler procedure.

Which Firms Are Influencing Competition In The Alzheimer’s Disease Diagnostic Market?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Get The Full Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Which Geographic Region Dominates The Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Alzheimer’s Disease Diagnostic Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2026, By The Business Research Company

Autism Spectrum Disorder Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorder-diagnostics-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Alzheimer’s Disease Diagnostic Market From 2026 To 2030?

The alzheimer’s disease diagnostic market has experienced substantial expansion in recent years. It is anticipated to grow from $7.26 billion in 2025 to $8.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The historical increase in this market can be ascribed to the rising occurrence of alzheimer’s disease, heightened understanding of neurodegenerative conditions, the use of MRI and PET imaging, the proliferation of diagnostic centers and hospitals, and financial contributions to cognitive assessment research.

The alzheimer’s disease diagnostic market size is poised for significant expansion over the next few years. It is expected to reach $11.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.3%. This anticipated growth is fueled by the development of innovative biomarkers and imaging tracers, the incorporation of AI for earlier detection, increasing government and private funding directed towards Alzheimer’s research, the spread of personalized medicine initiatives, and a rise in multi-center clinical trials. Prominent trends expected during this forecast period include a greater embrace of biomarker-based diagnostics, an increasing application of neuroimaging techniques for early identification, an uptick in cognitive assessment testing, the broadened availability of genetic testing for Alzheimer’s risk evaluation, and the integration of multi-modal diagnostic strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Leading Drivers Are Supporting The Alzheimer’s Disease Diagnostic Market Expansion?

The anticipated expansion of the Alzheimer’s disease diagnostic market is attributed to the rising incidence of chronic diseases. Conditions like cardiovascular disease, diabetes, and hypertension are deeply linked to a heightened risk of Alzheimer’s and other forms of dementia, thereby boosting the need for timely and precise diagnostic tools. A primary contributor to this surge in chronic diseases is the global increase in sedentary habits, with extensive research consistently demonstrating considerably higher rates of conditions like diabetes and cardiovascular disease among those with inactive lifestyles. Alzheimer’s diagnostics aid healthcare systems by facilitating early detection, allowing for prompt interventions, and assisting in patient management to retard the advancement of the disease. For example, data from November 2023, provided by Heritage Health Services, a US-based nonprofit healthcare research organization, indicated that 6.7 million Americans aged 65 or above were affected by Alzheimer’s dementia. The prevalence escalated with age: 5.0% for 65–74 years, 13.1% for 75–84 years, and 33.3% for 85+ years. Projections show this figure reaching almost 13 million by 2050. Consequently, the escalating prevalence of chronic disease is fueling the expansion of the Alzheimer’s disease diagnostic market.

How Is The Alzheimer’s Disease Diagnostic Market Categorized Across Its Segment Groups?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

What Emerging Trends Are Seen In The Alzheimer’s Disease Diagnostic Market?

Leading companies in the Alzheimer’s disease diagnostic market are concentrating on enhancing blood-based biomarker tests, a development expected to streamline the diagnostic process for Alzheimer’s disease. This approach aims to lessen dependence on more invasive procedures and improve patients’ access to timely treatment. For example, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, which serves as a biomarker for Alzheimer’s pathology, demonstrating clinical sensitivity and specificity in blood. Traditional methods for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are often expensive, invasive, and not broadly accessible. Additionally, the LucentAD p-Tau 217 test integrates Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, ensuring remarkable accuracy and a simpler procedure.

Which Firms Are Influencing Competition In The Alzheimer’s Disease Diagnostic Market?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Get The Full Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Which Geographic Region Dominates The Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Alzheimer’s Disease Diagnostic Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2026, By The Business Research Company

Autism Spectrum Disorder Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorder-diagnostics-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Alzheimer’s Disease Diagnostic Market From 2026 To 2030?

The alzheimer’s disease diagnostic market has experienced substantial expansion in recent years. It is anticipated to grow from $7.26 billion in 2025 to $8.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The historical increase in this market can be ascribed to the rising occurrence of alzheimer’s disease, heightened understanding of neurodegenerative conditions, the use of MRI and PET imaging, the proliferation of diagnostic centers and hospitals, and financial contributions to cognitive assessment research.

The alzheimer’s disease diagnostic market size is poised for significant expansion over the next few years. It is expected to reach $11.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.3%. This anticipated growth is fueled by the development of innovative biomarkers and imaging tracers, the incorporation of AI for earlier detection, increasing government and private funding directed towards Alzheimer’s research, the spread of personalized medicine initiatives, and a rise in multi-center clinical trials. Prominent trends expected during this forecast period include a greater embrace of biomarker-based diagnostics, an increasing application of neuroimaging techniques for early identification, an uptick in cognitive assessment testing, the broadened availability of genetic testing for Alzheimer’s risk evaluation, and the integration of multi-modal diagnostic strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Leading Drivers Are Supporting The Alzheimer’s Disease Diagnostic Market Expansion?

The anticipated expansion of the Alzheimer’s disease diagnostic market is attributed to the rising incidence of chronic diseases. Conditions like cardiovascular disease, diabetes, and hypertension are deeply linked to a heightened risk of Alzheimer’s and other forms of dementia, thereby boosting the need for timely and precise diagnostic tools. A primary contributor to this surge in chronic diseases is the global increase in sedentary habits, with extensive research consistently demonstrating considerably higher rates of conditions like diabetes and cardiovascular disease among those with inactive lifestyles. Alzheimer’s diagnostics aid healthcare systems by facilitating early detection, allowing for prompt interventions, and assisting in patient management to retard the advancement of the disease. For example, data from November 2023, provided by Heritage Health Services, a US-based nonprofit healthcare research organization, indicated that 6.7 million Americans aged 65 or above were affected by Alzheimer’s dementia. The prevalence escalated with age: 5.0% for 65–74 years, 13.1% for 75–84 years, and 33.3% for 85+ years. Projections show this figure reaching almost 13 million by 2050. Consequently, the escalating prevalence of chronic disease is fueling the expansion of the Alzheimer’s disease diagnostic market.

How Is The Alzheimer’s Disease Diagnostic Market Categorized Across Its Segment Groups?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

What Emerging Trends Are Seen In The Alzheimer’s Disease Diagnostic Market?

Leading companies in the Alzheimer’s disease diagnostic market are concentrating on enhancing blood-based biomarker tests, a development expected to streamline the diagnostic process for Alzheimer’s disease. This approach aims to lessen dependence on more invasive procedures and improve patients’ access to timely treatment. For example, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, which serves as a biomarker for Alzheimer’s pathology, demonstrating clinical sensitivity and specificity in blood. Traditional methods for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are often expensive, invasive, and not broadly accessible. Additionally, the LucentAD p-Tau 217 test integrates Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, ensuring remarkable accuracy and a simpler procedure.

Which Firms Are Influencing Competition In The Alzheimer’s Disease Diagnostic Market?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Get The Full Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Which Geographic Region Dominates The Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Alzheimer’s Disease Diagnostic Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2026, By The Business Research Company

Autism Spectrum Disorder Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorder-diagnostics-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Alzheimer’s Disease Diagnostic Market Over The 2026–2030 Period?

In recent years, the size of the alzheimer’s disease diagnostic market has experienced rapid expansion. It is projected to expand from $7.26 billion in 2025 to $8.03 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.6%. Historically, this expansion has stemmed from factors such as the increasing prevalence of alzheimer’s disease, greater public awareness of neurodegenerative disorders, the integration of MRI and PET imaging techniques, the proliferation of diagnostic centers and hospitals, and enhanced investment in cognitive assessment research.

The alzheimer’s disease diagnostic market is projected to undergo significant expansion in the coming years, with its size expected to reach $11.89 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period is propelled by factors such as the development of novel biomarkers and imaging tracers, the integration of artificial intelligence for early diagnosis, a surge in government and private funding for alzheimer’s research, the expansion of personalized medicine initiatives, and an increase in multi-center clinical trials. Noteworthy trends predicted for this period include the rising adoption of biomarker-based diagnostics, increased utilization of neuroimaging techniques for early detection, a growth in cognitive assessment testing, the expansion of genetic testing for alzheimer’s risk assessment, and the integration of multi-modal diagnostic approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What Underlying Factors Are Accelerating The Growth Of The Alzheimer’s Disease Diagnostic Market?

The projected expansion of the Alzheimer’s disease diagnostic market is anticipated due to the rising prevalence of chronic conditions. Conditions like cardiovascular disease, diabetes, and hypertension are closely linked to an elevated likelihood of developing Alzheimer’s and other dementias, consequently stimulating the need for prompt and precise diagnostic tools. A primary contributor to the increase in chronic diseases stems from the widespread adoption of sedentary lifestyles, given that extensive epidemiological studies consistently demonstrate considerably higher occurrences of conditions like diabetes and cardiovascular disease among individuals with low physical activity. Alzheimer’s diagnostics assist healthcare systems by facilitating early detection, allowing for prompt interventions, and directing patient care to decelerate the progression of the disease. As an illustration, data from November 2023, provided by Heritage Health Services, a US-based nonprofit organization dedicated to healthcare research, indicated that 6.7 million Americans aged 65 or older suffered from Alzheimer’s dementia, with its prevalence escalating with age: 5.0% for 65–74 years, 13.1% for 75–84 years, and 33.3% for 85+ years. Projections suggest this figure will climb to nearly 13 million by 2050. Consequently, the growing incidence of chronic conditions is fueling the expansion of the Alzheimer’s disease diagnostic market.

How Is The Alzheimer’s Disease Diagnostic Market Segmented Across Key Categories?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Which Upcoming Trends Are Expected To Influence The Alzheimer’s Disease Diagnostic Market?

Leading companies operating within the Alzheimer’s disease diagnostic market are concentrating on advancements in blood-based biomarker tests. This focus is anticipated to streamline the diagnostic process for Alzheimer’s disease, lessening the dependence on more intrusive procedures and enhancing patients’ access to timely treatment. For instance, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, a biomarker for Alzheimer’s pathology that demonstrates clinical sensitivity and specificity in blood. Traditional methods for cerebrospinal fluid (CSF) biomarkers, including positron emission tomography (PET) or lumbar puncture, are both costly, invasive, and not broadly accessible. Additionally, this test combines Quanterix’s ultra-sensitive Simoa® technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, leading to excellent accuracy and a simpler process.

Who Are The Dominant Players Shaping The Alzheimer’s Disease Diagnostic Market Landscape?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Read the full alzheimer’s disease diagnostic market report here:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Which Region Is Projected To Dominate The Alzheimer’s Disease Diagnostic Market During The Forecast Period?

North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Alzheimer’s Disease Diagnostic Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2026, By The Business Research Company

alzheimers drugs global market report

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

neurological biomarkers global market report

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

autism spectrum disorder diagnostics global market report

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorder-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model